BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Press Releases

  DiFusion to Define Therapeutic Biomaterials Category at NASS 2026

  September 29, 2026

   · 

  7 min read
• Press Releases

  Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

  September 29, 2026

   · 

  11 min read
• Press Releases

  Claris Bio Announces Oral Presentations at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting and Eyecelerator @ AAO

  September 29, 2026

   · 

  2 min read
• Press Releases

  Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

  September 29, 2026

   · 

  6 min read
• Press Releases

  Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

  September 29, 2026

   · 

  6 min read
• Press Releases

  Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026

  September 29, 2026

   · 

  1 min read
• Press Releases

  VB Spine Announces FDA Breakthrough Device Designation for New Blood Test Designed to Identify Patients at Risk for Scoliosis Progression

  September 29, 2026

   · 

  4 min read
• Press Releases

  Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

  September 29, 2026

   · 

  6 min read
• Press Releases

  TECPR2 Research Foundation and Forge Biologics Announce AAV Development and Manufacturing Partnership to Advance Gene Therapy for TECPR2

  September 29, 2026

   · 

  4 min read
• Press Releases

  Enveda Announces Late-Breaker Oral Presentation of New Mechanistic and Biomarker Data from the Phase 1b Trial of ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, at the Upcoming EADV 2026 Congress

  September 29, 2026

   · 

  3 min read